Hetrombopag
A Novel Small-Molecule, Orally Bioavailable, Non-Peptide Thrombopoietin Receptor Agonist
Thrombopotetin regulates the production of platelets by activation of the thrombopoietin receptor (TPOR). TPOR agonists are novel treatments for thrombocytopenia.
Hetrombopag is a TPOR agonist being developed to address aplastic anemia and idiopathic thrombocytopenic purpura. Hetrombopag has shown to increase platelet count in both animal models and human.
One phase III clinical trial to treat idiopathic thrombocytopenic purpura is ongoing in China.
Vunakizumab
A Human Monoclonal Immunoglobulin for IL-17-Related Autoimmune Diseases
Interleukin 17 (IL-17) is a pro-inflammatory cytokine, which is associated with numerous immune regulatory functions. IL-17 inhibitors are being investigated as possible treatments for autoimmune disease, such as rheumatoid arthritis, psoriasis, and inflammatory bowel disease.
Vunakizumab, a clinical-stage humanized monoclonal lgG1 antibody, targets both human IL-17A homodimer and IL-17A/F heterodimer to address autoimmune diseases.
Two phase I trials in healthy population were completed in China and Australia, respectively. Another two phase I trials are ongoing in China. A double-blind, randomized, international multicenter phase I/II trial on moderate-to-severe chronic plaque psoriasis patients is also ongoing.
SHR4640
URAT1 Inhibitor for Treatment of Hyperuricemia and Gout
Hyperuricemia and gout are metabolic diseases caused by chronic elevation of serum uric acid levels. Uric acids in the renal tubules are re-absorbed into the body by uric acid transporter 1 (URAT1). Inhibition of URAT1 increases urinary excretion of uric acid.
SHR4640 is a selective inhibitor of URAT1 being developed as an oral, once-daily treatment for the chronic management of hyperuricemia in patients with gout.
SHR4640 is currently being evaluated in one phase I, one phase II trial in China and in one phase I trial in Australia.
SHR0302
A Novel Small-Molecule JAK Inhibitor
JAK-STAT signaling pathway involves in the production of multiple inflammatory cytokines in the pathological processes of autoimmune diseases.
SHR0302 is a clinical-stage JAK1 inhibitor being developed to address rheumatoid arthritis, ulcerative colitis, and Crohn’s disease.
SHR0302 is currently in phase II clinical development in China.
On Jan 5th 2018, Arcutis obtained the U.S., EU, and Japan rights for the development of topical SHR0302 for dermatology disorders from Hengrui.